AbbVie to Acquire Apogee Therapeutics for $10.9 Billion

Paul, Weiss is advising AbbVie in its $10.9 billion all-cash acquisition of Apogee Therapeutics, a clinical-stage biotechnology company advancing novel biologics for the treatment of dermatologic, respiratory and other related inflammatory and immunological diseases. The acquisition, announced on June 22, is expected to be completed in the third quarter of 2026, pending shareholder and regulatory approvals.

The Paul, Weiss team is led by corporate partners Krishna Veeraraghavan and Benjamin Goodchild, and includes corporate partners Julie Ann Lamm and Patricia Vaz de Almeida; intellectual property partners Jeffrey Osterman and Brianna van Kan; executive compensation partner Matthew Friestedt; tax partner Brian Krause; antitrust partners Scott Sher, Jesse Solomon, Nicole Kar and Lauren O’Brien; real estate partner Ida Nowaid; litigation partners Elizabeth Weiswasser, Mark Mendelsohn and Geoffrey Chepiga and counsel Audrey Paquet, Natalie Kennedy, Benjamin Klein and Josh Thompson.